Sylvia Cheung
Director of Finance/CFO bei OCULIS HOLDING AG
Vermögen: 805 036 $ am 31.03.2024
Profil
Sylvia Cheung is currently the Chief Financial Officer at Oculis Holding AG since 2020.
Prior to this, she worked as the Chief Financial Officer & Treasurer at Anika Therapeutics, Inc. from 2005 to 2020.
Before that, she was a Principal at Transkaryotic Therapies, Inc. from 2000 to 2005 and a Senior Audit Associate at PricewaterhouseCoopers LLP from 1995 to 2000.
She also served as the General Manager at Anika Therapeutics Srl.
Ms. Cheung holds an MBA from Boston University and an undergraduate degree from the University of Massachusetts.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
OCULIS HOLDING AG
0,18% | 31.12.2023 | 66 808 ( 0,18% ) | 805 036 $ | 31.03.2024 |
Aktive Positionen von Sylvia Cheung
| Unternehmen | Position | Beginn |
|---|---|---|
| OCULIS HOLDING AG | Director of Finance/CFO | 01.09.2020 |
Ehemalige bekannte Positionen von Sylvia Cheung
| Unternehmen | Position | Ende |
|---|---|---|
| ANIKA THERAPEUTICS, INC. | Director of Finance/CFO | 10.08.2020 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Corporate Officer/Principal | - |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Corporate Officer/Principal | 01.01.2000 |
Ausbildung von Sylvia Cheung
| University of Massachusetts | Undergraduate Degree |
| Boston University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ANIKA THERAPEUTICS, INC. | Health Technology |
| OCULIS HOLDING AG | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | Commercial Services |
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
